Luminopia
Luminopia is a Cambridge, MA-based digital therapeutics company that developed Luminopia One, the only FDA-cleared VR-based digital therapeutic for amblyopia in children ages 4-12. It sells by prescription through pediatric eye care providers, with fulfillment via CoAssist Pharmacy and Pentec Health and coverage from major insurance payers.
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Luminopia does
Luminopia, Inc. is a privately held, Cambridge, Massachusetts-based digital therapeutics company founded in 2015-2016 that develops Luminopia One, an FDA-cleared VR-based digital therapeutic for amblyopia ("lazy eye") in children ages 4-12. The product works by streaming modified television content through a provided VR headset, applying dichoptic masking and contrast reduction to the stronger eye so that the brain learns to combine input from both eyes. Luminopia received FDA De Novo clearance in October 2021 for children ages 4-7 and expanded the indication in April 2025 to ages 8-12. Clinical evidence includes a Phase 3 pivotal trial of 117 patients showing significant vision improvement at 12 weeks (p=0.001), 85% median treatment completion, and 94% parental preference over patching.
Luminopia monetizes through a prescription-based, subscription digital therapeutic model. Pediatric ophthalmologists, optometrists, and orthoptists prescribe Luminopia One through EHR-integrated electronic prescribing, with fulfillment handled by partner pharmacy CoAssist Pharmacy (Orlando, FL) and additional distribution via a 2025 partnership with Pentec Health. The product is reimbursed by Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health. The commercial motion is enterprise field sales, supported by a healthcare provider adherence portal (hcp.luminopia.com) that surfaces patient compliance data back to prescribers. A curated content library of 75 TV shows / 3,100+ episodes — licensed from DreamWorks, Nelvana, Sony/Crunchyroll, Pokémon, Sesame Workshop, Nickelodeon, PBS Kids, and NBCUniversal — drives the engagement layer and is a key commercial differentiator.
The company has raised approximately $21.7 million in cumulative funding across a 2022 $5.7M seed extension (led by ShangBay Capital, with Sony Innovation Fund, The Vertical Group, and SSI Strategy) and a 2023 $16M Series A (led by U.S. Venture Partners). It operates with 11-50 employees, a lean commercial organization, and a development pipeline aimed at extending the platform to additional neuro-visual disorders including strabismus and intermittent exotropia. Leadership includes co-founder and CEO Scott Xiao (MIT TR Innovators Under 35, Forbes 30 Under 30), co-founder and Chairman Dean Travers (Thiel Fellow), COO Hank Wu (formerly Biogen, Evelo Biosciences), CBO Brion Raymond (formerly Genentech, Clearside Biomedical), VP of Commercial Strategy Drew Mowery (formerly Genentech, bluebird bio, Ultragenyx), and VP of Engineering Sunny Atwal (formerly Moth+Flame, Littlstar). Strategic board members include Robert Langer (MIT, Moderna co-founder) and representatives from USVP and ShangBay Capital.
Luminopia firmographics
Firmographics- Name
- Luminopia
- Legal name
- Luminopia, Inc.
- Website
- https://luminopia.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Luminopia is a Cambridge, MA-based digital therapeutics company that developed Luminopia One, the only FDA-cleared VR-based digital therapeutic for amblyopia in children ages 4-12. It sells by prescription through pediatric eye care providers, with fulfillment via CoAssist Pharmacy and Pentec Health and coverage from major insurance payers.
- Ownership category
- akta.pro rank
Luminopia industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)
- akta.pro primary industry
- Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)
- akta.pro secondary industry
- Vision Therapy & Orthoptics (HLAKAKAM)
Keywords
Where Luminopia is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Luminopia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Prescription Digital Therapeutic Subscription: Luminopia generates revenue through a prescription-based digital therapeutic model. Healthcare providers prescribe the treatment, and patients receive the VR headset and ongoing therapy through pharmacy fulfillment. The treatment is covered by major insurance providers including Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health, indicating a reimbursement-based revenue model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Prescription-based digital therapeutic for amblyopia |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Luminopia product offering
Product offeringCore offering
Luminopia develops and sells Luminopia One, an FDA-cleared digital therapeutic that uses a VR headset to stream modified TV content for binocular therapy in children ages 4-12 with amblyopia (lazy eye). The treatment is prescribed by pediatric ophthalmologists and optometrists, dispensed through CoAssist Pharmacy, and covered by major US insurance payers. The company also offers a healthcare provider Adherence Portal for monitoring patient compliance.
Product overview
Luminopia is a digital health company offering a single FDA-cleared product, Luminopia One, which uses VR headsets to stream TV content as therapy for amblyopia (lazy eye) in children ages 4-12. The product employs a dual-acting binocular mechanism involving contrast reduction and dichoptic masking to encourage both eyes to work together. Luminopia One is supplemented by a provider-facing Adherence Portal for monitoring patient compliance. The company's development pipeline explores applications for additional neuro-visual conditions including intermittent exotropia and strabismus. Content partnerships with entertainment companies (DreamWorks, Nelvana, Sony, Pokemon, Sesame Street, Nickelodeon, PBS, NBCUniversal, Crunchyroll) provide the TV content streamed through the VR system.
Differentiator
Problem solved
Functional benefit
Products and services
- Luminopia One FDA-cleared digital therapeutic using VR headsets to stream TV shows for amblyopia treatment in children ages 4-12. Uses a dual-acting binocular mechanism that reduces contrast to the stronger eye and applies dichoptic masking to encourage both eyes to work together. Treatment is one hour per day, six days per week, with significant vision improvement shown in as early as 4 weeks in a 12-week clinical trial.
- Luminopia Adherence Portal Healthcare provider portal for monitoring patient treatment compliance, displaying weekly and overall adherence trends for each Luminopia One patient. Used by physicians and office staff to track treatment progress.
Quantifiable outcome
- 85% median treatment completion rate in clinical trial
- +4 more outcomes
Companies that use Luminopia
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Luminopia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Luminopia partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered content_partner, distribution_partner, fulfillment_partner and coverage_partner.
- Crunchyrollcontent_partnerCollaboration with Crunchyroll (Sony Pictures Entertainment subsidiary) to incorporate anime content into Luminopia's platform for treating pediatric amblyopia using a digital therapeutic approach.
- Pokémon Company Internationalcontent_partnerContent licensing agreement to integrate Pokémon content into Luminopia's FDA-cleared amblyopia therapy platform to boost patient engagement and treatment adherence among children.
- Pentec Health Inc.distribution_partnerPartnership announced March 2025 to expand distribution of Luminopia's digital therapeutics for amblyopia and mild strabismus.
- Sesame Workshopcontent_partnerEntertainment content partner providing Sesame Street content for Luminopia's curated content library used in vision therapy.
- Dreamworkscontent_partnerEntertainment content partner providing content including How to Train Your Dragon and Puss in Boots for Luminopia's therapy platform.
- Nelvanacontent_partnerEntertainment content partner providing content for Luminopia's curated content library.
- Nickelodeoncontent_partnerEntertainment content partner providing content including SpongeBob SquarePants, Wild Kratts, and The Loud House for Luminopia's therapy platform.
- PBS Kidscontent_partnerEntertainment content partner providing PBS Kids content for Luminopia's curated content library.
- NBCUniversalcontent_partnerEntertainment content partner providing content for Luminopia's curated content library.
- CoAssist Pharmacyfulfillment_partnerPharmacy fulfillment partner that receives electronic prescriptions from healthcare providers and handles shipment of VR headsets and therapy materials to patients.
- CareFirst BlueCross BlueShieldcoverage_partnerApproved coverage for Luminopia's FDA-cleared digital therapeutic treatment for amblyopia in children aged 4 to 12.
- Anthem Blue Cross Blue Shieldcoverage_partnerInsurance coverage approved for Luminopia's amblyopia treatment.
- Highmark Healthcoverage_partnerInsurance coverage approved for Luminopia's pediatric amblyopia treatment.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Luminopia competitors and assessment
Company assessmentDirect peers
- Akili Interactive: Maker of EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. Closest direct comparable: prescription DTx business model targeting pediatric prescribers, reimbursed by payers, with software-led therapy delivered via consumer hardware.
- Vivid Vision: Developed VR-based vision therapy software for amblyopia, strabismus, and other binocular vision disorders. Direct competitor in the VR digital therapy category for the same patient population Luminopia targets.
- Bynocs: Offers clinician-prescribed dichoptic digital therapy for amblyopia using web/browser-based delivery. Competes in the same binocular digital therapeutics category for amblyopia patients.
- AmblyoPlay: Software-based vision therapy for amblyopia and other binocular disorders delivered via home computers/tablets. Direct competitor in digital amblyopia therapy, though primarily consumer-direct rather than prescription-based.
- Pear Therapeutics: Pioneer in prescription digital therapeutics (reSET, reSET-O) that pursued FDA-cleared, payer-reimbursed software therapeutics for CNS indications. Closest historical peer for the prescription DTx commercial model, despite bankruptcy and asset divestiture in 2023.
- Cognoa: Pediatric-focused digital health company with FDA-authorized autism diagnostic and therapeutic digital products. Comparable as a pediatric prescription DTx company pursuing payer reimbursement for childhood neuro-developmental conditions.
- Click Therapeutics: Prescription digital therapeutics company developing software-delivered therapies across multiple indications, with pharma partnerships (e.g., Otsuka). Comparable business model targeting FDA-cleared, payer-reimbursed digital therapeutics.
- Big Health: Digital therapeutics company whose Sleepio product is FDA-cleared and covered by major insurers for insomnia. Comparable prescription DTx commercial playbook: FDA pathway, payer coverage, employer/health system distribution.
Broad incumbents
- Novartis: Global pharmaceutical incumbent with established pediatric ophthalmology presence; competes in the amblyopia treatment paradigm with atropine drops and has the resources to develop or acquire competing digital therapeutics.
- Otsuka Pharmaceutical: Large pharmaceutical company that has invested heavily in digital therapeutics (e.g., partnership with Akili, Click Therapeutics). Represents both a potential strategic acquirer and an incumbent player with pediatric/commercial reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights8 records
Customer concentration
Luminopia social profiles
Digital presenceLuminopia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Luminopia leadership team
Management profileNumber of profiles
Profiles9 records
Luminopia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Luminopia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Luminopia
What does Luminopia do?
Luminopia develops and sells Luminopia One, an FDA-cleared digital therapeutic that uses a VR headset to stream modified TV content for binocular therapy in children ages 4-12 with amblyopia (lazy eye). The treatment is prescribed by pediatric ophthalmologists and optometrists, dispensed through CoAssist Pharmacy, and covered by major US insurance payers. The company also offers a healthcare provider Adherence Portal for monitoring patient compliance.
Is Luminopia a public or private company?
Luminopia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Luminopia founded?
Luminopia was founded in 2016. It employs 11 to 50 people.
Where is Luminopia based?
Luminopia is headquartered in Cambridge, United States, in the North America region.
How does Luminopia make money?
One revenue line is on record: prescription Digital Therapeutic Subscription.
Who are Luminopia's main competitors?
Direct peers on record are Akili Interactive, Vivid Vision, Bynocs, AmblyoPlay, Pear Therapeutics, Cognoa, Click Therapeutics and Big Health. Broad incumbents are Novartis and Otsuka Pharmaceutical.
Does Luminopia have an API?
No public API is recorded for Luminopia.
What industry is Luminopia in?
Luminopia's product category is Digital Therapeutics. Its primary akta.pro industry code is HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment), with a secondary code of HLAKAKAM, Vision Therapy & Orthoptics. Its NAICS code is 334510 and its SIC code is 3845.